NCI-2024-09213

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-Label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the treatment of Selected HER2-mutated or Overexpressed/ Amplified Solid Tumours

This research study is investigating a new oral drug called Zongertinib for its effectiveness and safety in patients with various types of solid tumors that have specific abnormalities in the HER2 gene (mutations, overexpression, or amplification). HER2 Human Epidermal growth factor Receptor 2 is a gene that makes a protein found on the outside of all breast cells. It's involved in cell growth and is a common target in cancer therapy.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06581432

Clinical Trial Site: Sinai

To see all available clinical trials click here.